APA (7th ed.) Citation

Gide, T. N., Pires da Silva, I., Quek, C., Ferguson, P. M., Batten, M., Shang, P., . . . Wilmott, J. S. (2021). Clinical and Molecular Heterogeneity in Patients with Innate Resistance to Anti-PD-1 +/− Anti-CTLA-4 Immunotherapy in Metastatic Melanoma Reveals Distinct Therapeutic Targets. Cancers, 13(13), 3186. https://doi.org/10.3390/cancers13133186

Chicago Style (17th ed.) Citation

Gide, Tuba N., et al. "Clinical and Molecular Heterogeneity in Patients with Innate Resistance to Anti-PD-1 +/− Anti-CTLA-4 Immunotherapy in Metastatic Melanoma Reveals Distinct Therapeutic Targets." Cancers 13, no. 13 (2021): 3186. https://doi.org/10.3390/cancers13133186.

MLA (9th ed.) Citation

Gide, Tuba N., et al. "Clinical and Molecular Heterogeneity in Patients with Innate Resistance to Anti-PD-1 +/− Anti-CTLA-4 Immunotherapy in Metastatic Melanoma Reveals Distinct Therapeutic Targets." Cancers, vol. 13, no. 13, 2021, p. 3186, https://doi.org/10.3390/cancers13133186.